Badar M. Mian, MD

"This study demonstrates that for up to 10 years after diagnosis, approximately 50% of men with low-risk prostate cancer can safely remain on AS, without cancer progression or treatment, since less than 1% died of prostate cancer," writes Badar M. Mian, MD.

"In deciding whom to discharge within hours of a less invasive but major surgery, we must ask ourselves which master we are serving: the insurer, the administrator, or our own ego," writes Badar M. Mian, MD.

"This large registry study with data from varied practice settings, incorporating the most commonly used treatment modalities, provides useful data on the long-term mortality outcomes," writes Badar M. Mian, MD.

"FPSA is an important, inexpensive, and readily available test in our risk-stratification toolbox," writes Badar M. Mian, MD.

"To avoid unnecessary treatment, percutaneous biopsy of the small renal mass has increased for the past several years, but its use remains highly variable," writes Badar M. Mian, MD.

"The study demonstrated that AS rate in the MUSIC cohort, which in 2014 had been lower than in the SEER cohort, increased rapidly, from approximately 20% in 2014 to nearly 50% in 2019, whereas the SEER cohort showed only a modest increase," writes Badar M. Mian, MD.

The current study is welcome news as it lends further support to the use of intravesical Gem/Doce as a safe and effective option that has the potential to become a new standard of care for high-risk NMIBC.

"It will only be when the indications for focal therapy are expanded to higher-grade and larger tumors that we will begin to learn about the true efficacy of this approach," writes Badar M. Mian, MD.

"It’s apparent that reducing overdiagnosis alone may not necessarily reduce over treatment, and that separate and specific focus on prevention of over treatment is still needed," Badar M. Mian, MD, writes.

"Up-front CN is associated with a survival benefit in selected patients with mRCC treated with either targeted therapy or ICI therapy," writes Badar M. Mian, MD.

"Ultimately, it will be the treating physician’s responsibility to identify cost-effective alternatives and available resources to help mitigate the financial toxicity incurred from novel cancer therapies," writes Badar M. Mian, MD.

"It is evident...that the safety of 5-ARIs as it relates to prostate cancer outcomes is contingent upon the clinician understanding its effect on PSA level and making appropriate adjustments to ensure timely deployment of diagnostic imaging and biopsy," writes Badar M. Mian, MD.

Randomized controlled trial compares intracorporeal robotic technique with open surgery.

"It’s very possible that the PSA screening-detected high-risk prostate cancer portends a more favorable outlook when compared with the pre-PSA era, regardless of the type of primary therapy utilized," writes Badar M. Mian, MD.

"If adequate cancer control can be achieved by focal or partial-gland treatment, then the favorable adverse event profile could make this a preferred option for a number of men with localized intermediate-risk (and possibly selected high-risk) prostate cancer," writes Badar M. Mian, MD.

"It is worth remembering that injudicious use of PSA test, and the downstream consequences of overtreatment and complications, can obscure the benefits associated with PSA-based early detection of prostate cancer," writes Badar M. Mian, MD.

"It appears that the TR and TP biopsy procedures are essentially comparable in various aspects of the procedure," writes Badar M. Mian, MD.

"This study provides credible support for the expectation that post-RC HRQOL should recover and improve over the first 2 years after RC, and provides a benchmark for comparisons with future bladder preservation strategies," writes Badar M. Mian, MD.

"This large cohort study confirms the safety of AS, as shown in the low rate of metastasis or death, including those who subsequently converted to treatment," writes Badar M. Mian, MD.

"It is apparent from the results of these 2 studies that neither the higher-dose RT nor early RT after RP provide sufficient oncological benefits to justify the adverse impact on functional outcomes and HRQOL," writes Badar M. Mian, MD.

"The use of 177Lu-PSMA-617 significantly extended both the imaging-based survival and overall survival," writes Badar M. Mian, MD.

"This study provides important and clinically useful information that can be used to plan the intensity of treatment and counsel our patients regarding the cancer-related and QOL-related outcomes after treatment," writes Badar M. Mian, MD.

"Three decades into prostate-specific antigen screening–detected prostate cancer, the prognostic and therapeutic impacts of various types of pelvic lymph node dissection remain unclear," writes Badar M. Mian, MD.

The trend persists even after adjusting for surgical volume and experience.

"It is essential for us to be vigilant about all the complications, whether local or systemic, associated with intravesical BCG," writes Badar M. Mian, MD.

The technique fails to demonstrate benefits for prostate cancer recurrence and metastases.

"Despite some heterogeneity in the type and frequency of testing during the surveillance period, these results provide reassurance and increased confidence in the safe utilization of AS protocols for men with low-risk GG1, and selected GG2, prostate cancer," Mian writes.

PSA monitoring and early salvage therapy appear to be safest in these patients.

Cognitive screening is recommended in patients receiving androgen-deprivation therapy.

Survival outcomes are not compromised in men undergoing active surveillance, a recent study finds.